Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sestini

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2022
Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trialU Pastorino, M Boeri, S Sestini, et al.
Orphanet Journal of Rare Diseases|December 4, 2020
The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveysC Lampe, C Dionisi-Vici, C M Bellettato, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2001
Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trialP Correale, G Campoccia, K Y Tsang, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2022
Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trialU Pastorino, M Boeri, S Sestini, et al.
Orphanet Journal of Rare Diseases|December 4, 2020
The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveysC Lampe, C Dionisi-Vici, C M Bellettato, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2001
Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trialP Correale, G Campoccia, K Y Tsang, et al.
Pageof 8